Galligan Johnston solicitors have recently received instructions in a number of claims being brought by parents of children born with FACS (Foetal Anti-Convulsant Syndrome), an umbrella term used to describe a range of physical and learning disabilities known to be caused by certain anti-convulsant medication when taken to treat the symptoms of epilepsy either prior to or during pregnancy. Sodium Valproate, marketed by Sanofi as Epilim in Ireland, the UK and further afield, is one such drug which has been linked with significant risks of both physical and mental issues including spina bifida, autism and others. Sodium Vaproate was licensed in Ireland in the early 1980s but has been prescribed since the mid to late 1970s if not earlier, and continues to be distributed in Ireland, oftentimes without adequate or indeed any patient information regarding potential side effects.
Galligan Johnston are supporting OACS (the Organisation for Anti-Convulsant Syndrome) as it works to dramatically improve patient awareness of the risk of significant and life-limiting side effects for their children. We look forward to advancing these matters and to achieving long overdue justice for those affected.
If you suspect that you or your child may suffer from FACS please contact your medical professional immediately. You can also contact OACS at firstname.lastname@example.org. If you wish to discuss the matter further with us in confidence, please contact Sam Saarsteiner, partner, at 01-6344680, email@example.com or firstname.lastname@example.org.